Document is current
Any future updates will be listed below
-
Authors
Makker, Vicky https://orcid.org/0000-0001-9793-7614
Colombo, Nicoletta
Casado, Antonio
Santin, Alessandro D
Colomba, Emeline
Miller, David S https://orcid.org/0000-0002-8215-5887
Fujiwara, Keiichi
Pignata, Sandro
Yonemori, Kan
Kim, Yong Man
Baron-Hay, Sally
Ray-Coquard, Isabelle
Shapira-Frommer, Ronnie
Kristeleit, Rebecca https://orcid.org/0000-0003-3825-1326
Nishio, Shin https://orcid.org/0000-0003-2526-630X
Suzuki, Shiro
Guerra Alía, Eva M
Sanli, Ulus A
Selle, Frederic
Shikama, Ayumi
Martínez Rodríguez, Jorge L
Arik, Zafer
Arican, Ali
Sebastianelli, Alexandra
Yu, Zhou
McKenzie, Jodi
Kruger, Stephan
Meng, Robin
Okpara, Chinyere E
Lorusso, Domenica
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03517449 at ClinicalTrials.govnct03517449 at ClinicalTrials.govDocuments that mention this clinical trial
Outcomes and endpoints of relevance in gynecologic cancer clinical trials
https://doi.org/10.1136/ijgc-2022-003727
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study
https://doi.org/10.1136/ijgc-2021-002881
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
https://doi.org/10.1136/ijgc-2020-001822
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
https://doi.org/10.1200/jco.22.02152
Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775
https://doi.org/10.1136/jitc-2025-013713
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Documents that mention this clinical trial
Outcomes and endpoints of relevance in gynecologic cancer clinical trials
https://doi.org/10.1136/ijgc-2022-003727
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study
https://doi.org/10.1136/ijgc-2021-002881
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
https://doi.org/10.1136/ijgc-2020-001822
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
https://doi.org/10.1200/jco.22.02152
Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775
https://doi.org/10.1136/jitc-2025-013713
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
-
Funding
Funding for this research was provided by:
Eisai Inc., Nutley, NJ, USA (NA)
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (NA)
- License Information
